drugset / Trial / NCT00788294
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
Timeline
- Start
- 2008-11
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tanezumab | Monoclonal antibody | 5 mg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 10 mg | Intravenous |
| Comparator | Tanezumab | Monoclonal antibody | 19 mg | Intravenous |
Indications
No indication recorded.